DPP4 and chronic kidney disease: Older age, chronic kidney disease (OR 0.52, 95% CI 0.41–0.66), and concurrent use of dipeptidyl peptidase 4 inhibitors (DPP4i) (OR 0.09, 95% CI 0.09–0.10) significantly reduced the likelihood of SGLT2i use.